|
US8981061B2
(en)
|
2001-03-20 |
2015-03-17 |
Novo Nordisk A/S |
Receptor TREM (triggering receptor expressed on myeloid cells) and uses thereof
|
|
GB0426146D0
(en)
|
2004-11-29 |
2004-12-29 |
Bioxell Spa |
Therapeutic peptides and method
|
|
EP2068909B1
(en)
|
2007-03-30 |
2012-04-25 |
Ambrx, Inc. |
Modified fgf-21 polypeptides and their uses
|
|
EP2389190B1
(en)
|
2009-01-23 |
2018-09-19 |
Novo Nordisk A/S |
Fgf21 derivatives with albumin binder a-b-c-d-e- and their use
|
|
WO2011154349A2
(en)
*
|
2010-06-08 |
2011-12-15 |
Novo Nordisk A/S |
Fgf21 analogues and derivatives
|
|
EP2460527A1
(en)
*
|
2010-01-21 |
2012-06-06 |
Sanofi |
Pharmaceutical composition for treating a metabolic syndrome
|
|
CN103124562A
(zh)
*
|
2010-06-08 |
2013-05-29 |
诺沃—诺迪斯克有限公司 |
Fgf21的类似物和衍生物
|
|
EP2726511B1
(en)
|
2011-07-01 |
2019-08-07 |
NGM Biopharmaceuticals, Inc. |
Compositions, uses and methods for treatment of metabolic disorders and diseases
|
|
EP2548570A1
(en)
*
|
2011-07-19 |
2013-01-23 |
Sanofi |
Pharmaceutical composition for treating a metabolic syndrome
|
|
US9458214B2
(en)
|
2011-09-26 |
2016-10-04 |
Novartis Ag |
Dual function fibroblast growth factor 21 proteins
|
|
US9550830B2
(en)
|
2012-02-15 |
2017-01-24 |
Novo Nordisk A/S |
Antibodies that bind and block triggering receptor expressed on myeloid cells-1 (TREM-1)
|
|
HRP20171585T1
(hr)
|
2012-02-15 |
2017-12-01 |
Novo Nordisk A/S |
Antitijela koja vezuju i blokiraju aktivirajući receptor eksprimiran na mijeloičnim stanicama 1 (trem-1)
|
|
EP2814842B1
(en)
|
2012-02-15 |
2018-08-22 |
Novo Nordisk A/S |
Antibodies that bind peptidoglycan recognition protein 1
|
|
TW201420606A
(zh)
*
|
2012-08-22 |
2014-06-01 |
Lilly Co Eli |
同源二聚體蛋白
|
|
UA116217C2
(uk)
|
2012-10-09 |
2018-02-26 |
Санофі |
Пептидна сполука як подвійний агоніст рецепторів glp1-1 та глюкагону
|
|
US9290557B2
(en)
|
2012-11-28 |
2016-03-22 |
Ngm Biopharmaceuticals, Inc. |
Compositions comprising variants and fusions of FGF19 polypeptides
|
|
EP2925775B1
(en)
|
2012-11-28 |
2020-09-16 |
NGM Biopharmaceuticals, Inc. |
Compositions and methods for treatment of metabolic disorders and diseases
|
|
HRP20181300T1
(hr)
|
2012-12-21 |
2018-10-05 |
Sanofi |
Derivati eksendina-4 kao dvostruki glp1/gip- ili trostruki glp1/gip/glukagon agonisti
|
|
US9273107B2
(en)
|
2012-12-27 |
2016-03-01 |
Ngm Biopharmaceuticals, Inc. |
Uses and methods for modulating bile acid homeostasis and treatment of bile acid disorders and diseases
|
|
KR102724421B1
(ko)
|
2012-12-27 |
2024-10-30 |
엔지엠 바이오파마슈티컬스, 아이엔씨. |
담즙산 항상성의 조절 및 담즙산 질환 및 질병의 치료 방법
|
|
MX2015016564A
(es)
|
2013-06-20 |
2016-04-15 |
Novo Nordisk As |
Derivados de peptido similar al glucaton tipo 1 (glp-1) y uso de los mismos.
|
|
KR102178945B1
(ko)
|
2013-10-28 |
2020-11-13 |
엔지엠 바이오파마슈티컬스, 아이엔씨. |
암 모델 및 관련 방법
|
|
EP3080149A1
(en)
|
2013-12-13 |
2016-10-19 |
Sanofi |
Dual glp-1/glucagon receptor agonists
|
|
WO2015086728A1
(en)
|
2013-12-13 |
2015-06-18 |
Sanofi |
Exendin-4 peptide analogues as dual glp-1/gip receptor agonists
|
|
EP3080154B1
(en)
|
2013-12-13 |
2018-02-07 |
Sanofi |
Dual glp-1/gip receptor agonists
|
|
TW201609796A
(zh)
|
2013-12-13 |
2016-03-16 |
賽諾菲公司 |
非醯化之艾塞那肽-4(exendin-4)胜肽類似物
|
|
SI3097122T1
(sl)
|
2014-01-24 |
2020-07-31 |
Ngm Biopharmaceuticals, Inc. |
Protitelesa, ki se vežejo v domeni beta klotho 2, in metode za njihovo uporabo
|
|
TW201625670A
(zh)
|
2014-04-07 |
2016-07-16 |
賽諾菲公司 |
衍生自exendin-4之雙重glp-1/升糖素受體促效劑
|
|
TW201625669A
(zh)
|
2014-04-07 |
2016-07-16 |
賽諾菲公司 |
衍生自艾塞那肽-4(Exendin-4)之肽類雙重GLP-1/升糖素受體促效劑
|
|
TW201625668A
(zh)
|
2014-04-07 |
2016-07-16 |
賽諾菲公司 |
作為胜肽性雙重glp-1/昇糖素受體激動劑之艾塞那肽-4衍生物
|
|
WO2015183890A2
(en)
|
2014-05-28 |
2015-12-03 |
Ngm Biopharmaceuticals, Inc. |
Methods and compositions for the treatment of metabolic disorders and diseases
|
|
CA2951153A1
(en)
|
2014-06-16 |
2015-12-23 |
Ngm Biopharmaceuticals, Inc. |
Methods and uses for modulating bile acid homeostasis and treatment of bile acid disorders and diseases
|
|
US9932381B2
(en)
|
2014-06-18 |
2018-04-03 |
Sanofi |
Exendin-4 derivatives as selective glucagon receptor agonists
|
|
SI3172232T1
(sl)
|
2014-07-17 |
2024-05-31 |
Novo Nordisk A/S |
Na mesto usmerjena mutageneza protiteles TREM-1 za zmanjšanje viskoznosti
|
|
CN107108711B
(zh)
|
2014-10-23 |
2021-11-23 |
恩格姆生物制药公司 |
包含肽变异体的药物组合物及其使用方法
|
|
KR102854572B1
(ko)
|
2014-10-24 |
2025-09-02 |
브리스톨-마이어스 스큅 컴퍼니 |
변형된 fgf-21 폴리펩티드 및 그의 용도
|
|
US10434144B2
(en)
|
2014-11-07 |
2019-10-08 |
Ngm Biopharmaceuticals, Inc. |
Methods for treatment of bile acid-related disorders and prediction of clinical sensitivity to treatment of bile acid-related disorders
|
|
CN106999602B
(zh)
|
2014-11-27 |
2022-02-01 |
诺和诺德股份有限公司 |
Glp-1衍生物及其用途
|
|
WO2016097108A1
(en)
|
2014-12-17 |
2016-06-23 |
Novo Nordisk A/S |
Glp-1 derivatives and uses thereof
|
|
MY181181A
(en)
|
2014-12-23 |
2020-12-21 |
Novo Nordisk As |
Fgf21 derivatives and uses thereof
|
|
AR105319A1
(es)
|
2015-06-05 |
2017-09-27 |
Sanofi Sa |
Profármacos que comprenden un conjugado agonista dual de glp-1 / glucagón conector ácido hialurónico
|
|
AR105284A1
(es)
|
2015-07-10 |
2017-09-20 |
Sanofi Sa |
Derivados de exendina-4 como agonistas peptídicos duales específicos de los receptores de glp-1 / glucagón
|
|
US10800843B2
(en)
|
2015-07-29 |
2020-10-13 |
Ngm Biopharmaceuticals, Inc. |
Beta klotho-binding proteins
|
|
WO2017024182A1
(en)
|
2015-08-04 |
2017-02-09 |
Duke University |
Genetically encoded intrinsically disordered stealth polymers for delivery and methods of using same
|
|
KR102670157B1
(ko)
*
|
2015-10-28 |
2024-05-29 |
주식회사유한양행 |
이중 작용 단백질 및 이를 포함하는 약학적 조성물
|
|
KR102668200B1
(ko)
|
2015-10-28 |
2024-05-23 |
주식회사유한양행 |
지속형 fgf21 융합 단백질 및 이를 포함하는 약학적 조성물
|
|
JP6728352B2
(ja)
|
2015-11-09 |
2020-07-22 |
エヌジーエム バイオファーマシューティカルス,インコーポレーテッド |
胆汁酸に関係した障害の治療方法
|
|
US11752213B2
(en)
|
2015-12-21 |
2023-09-12 |
Duke University |
Surfaces having reduced non-specific binding and antigenicity
|
|
US11318186B2
(en)
|
2016-05-25 |
2022-05-03 |
Board Of Regents, The University Of Texas System |
Use of FGF21 in methods of increasing exocrine pancreatic secretion
|
|
US11467156B2
(en)
|
2016-06-01 |
2022-10-11 |
Duke University |
Nonfouling biosensors
|
|
CN106317226B
(zh)
|
2016-08-19 |
2017-09-05 |
安源医药科技(上海)有限公司 |
用于构建融合蛋白的连接肽
|
|
EP3502143A4
(en)
|
2016-08-19 |
2020-07-15 |
Ampsource Biopharma Shanghai Inc. |
BINDING PEPTIDE FOR THE CONSTRUCTION OF A FUSION PROTEIN
|
|
CN106279437B
(zh)
|
2016-08-19 |
2017-10-31 |
安源医药科技(上海)有限公司 |
高糖基化人凝血因子viii融合蛋白及其制备方法与用途
|
|
CA3034399A1
(en)
|
2016-08-26 |
2018-03-01 |
Ngm Biopharmaceuticals, Inc. |
Methods of treating fibroblast growth factor 19-mediated cancers and tumors
|
|
RU2019110848A
(ru)
|
2016-09-14 |
2020-10-15 |
Дьюк Юниверсити |
Наночастицы на основе триблочных полипептидов для доставки гидрофильных лекарственных средств
|
|
WO2018057847A1
(en)
|
2016-09-23 |
2018-03-29 |
Duke University |
Unstructured non-repetitive polypeptides having lcst behavior
|
|
AU2017358289C1
(en)
|
2016-11-10 |
2025-05-08 |
Yuhan Corporation |
Pharmaceutical composition for preventing or treating hepatitis, hepatic fibrosis, and hepatic cirrhosis comprising fusion proteins
|
|
EP3552022B1
(en)
*
|
2016-11-25 |
2021-06-09 |
Implexion AB |
Metabolic disorders
|
|
US11648200B2
(en)
|
2017-01-12 |
2023-05-16 |
Duke University |
Genetically encoded lipid-polypeptide hybrid biomaterials that exhibit temperature triggered hierarchical self-assembly
|
|
EP4470551A3
(en)
|
2017-03-14 |
2025-02-26 |
Sunshine Lake Pharma Co., Ltd. |
Dual-target fusion proteins comprising the fc portion of an immunoglobulin
|
|
CN108619490A
(zh)
*
|
2017-03-22 |
2018-10-09 |
天士力医药集团股份有限公司 |
一种长效化突变的人源成纤维生长因子的新用途
|
|
US11560416B2
(en)
|
2017-04-21 |
2023-01-24 |
Yuhan Corporation |
Method for producing dual function proteins and its derivatives
|
|
WO2018213320A1
(en)
|
2017-05-15 |
2018-11-22 |
Duke University |
Recombinant production of hybrid lipid-biopolymer materials that self-assemble and encapsulate agents
|
|
WO2019006374A1
(en)
|
2017-06-30 |
2019-01-03 |
Duke University |
ORDER AND DISORDER AS A DESIGN PRINCIPLE FOR STIMULI-SENSITIVE BIOPOLYMER NETWORKS
|
|
CN115109166B
(zh)
*
|
2017-11-24 |
2025-07-18 |
浙江道尔生物科技有限公司 |
一种治疗代谢疾病的多结构域活性蛋白
|
|
CN111518770B
(zh)
|
2017-12-19 |
2023-01-06 |
北京吉源生物科技有限公司 |
一种表达glp1和fgf21的干细胞及其用途
|
|
CN109942696A
(zh)
*
|
2017-12-21 |
2019-06-28 |
中国药科大学 |
长效化胰高血糖素样肽-1(glp-1)类似物及其应用
|
|
CN113603794B
(zh)
*
|
2018-01-11 |
2024-01-16 |
安源医药科技(上海)有限公司 |
用于调节血糖和脂质的增效型双功能蛋白
|
|
WO2019147954A1
(en)
|
2018-01-26 |
2019-08-01 |
Duke University |
Albumin binding peptide-drug (aibiped) conjugates and methods of making and using same
|
|
CN116098989A
(zh)
|
2018-02-08 |
2023-05-12 |
广东东阳光药业有限公司 |
Fgf21变体、融合蛋白及其应用
|
|
EA202092302A1
(ru)
|
2018-04-02 |
2021-02-02 |
Бристол-Майерс Сквибб Компани |
Антитела к trem-1 и их применения
|
|
WO2019213150A1
(en)
|
2018-04-30 |
2019-11-07 |
Duke University |
Stimuli-responsive peg-like polymer-based drug delivery platform
|
|
US11649275B2
(en)
|
2018-08-02 |
2023-05-16 |
Duke University |
Dual agonist fusion proteins
|
|
BR112021020071A2
(pt)
*
|
2019-04-11 |
2021-12-14 |
Jiangsu Hansoh Pharmaceutical Group Co Ltd |
Compostos agonistas duplos do receptor de glp-1 e gip e uso dos mesmos
|
|
CN114853908B
(zh)
|
2019-05-16 |
2024-06-07 |
浙江道尔生物科技有限公司 |
一种治疗代谢疾病的融合蛋白
|
|
US11512314B2
(en)
|
2019-07-12 |
2022-11-29 |
Duke University |
Amphiphilic polynucleotides
|
|
CN112279920B
(zh)
*
|
2019-07-25 |
2024-01-16 |
安源医药科技(上海)有限公司 |
FGF21 Fc融合蛋白、GLP-1 Fc融合蛋白及它们的组合治疗剂和用途
|
|
WO2021139744A1
(en)
*
|
2020-01-11 |
2021-07-15 |
Beijing Ql Biopharmaceutical Co., Ltd. |
Conjugates of fusion proteins of glp-1 and fgf21
|
|
US11981718B2
(en)
|
2020-05-27 |
2024-05-14 |
Ampsource Biopharma Shanghai Inc. |
Dual-function protein for lipid and blood glucose regulation
|
|
WO2024165571A2
(en)
|
2023-02-06 |
2024-08-15 |
E-Therapeutics Plc |
Inhibitors of expression and/or function
|
|
KR20250167609A
(ko)
|
2023-03-30 |
2025-12-01 |
노보 노르디스크 에이/에스 |
융합 화합물 및 그 용도
|
|
WO2025125576A2
(en)
|
2023-12-15 |
2025-06-19 |
E-Therapeutics Plc |
Inhibitors of expression and/or function
|
|
WO2025133348A1
(en)
|
2023-12-22 |
2025-06-26 |
E-Therapeutics Plc |
Inhibitors of expression and/or function
|
|
WO2025196502A1
(en)
|
2024-03-20 |
2025-09-25 |
North Carolina Agricultural & Technical State University |
Choline kinase inhibitors as a therapeutic treatment for obesity
|